2024-07-05 14:10:21 ET
Summary
- Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021.
- Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing other programs.
- With positive cash flow expected soon, a $150 million share repurchase plan, and strong financials, Aurinia is undervalued and worth considering for investment.
- A full investment analysis around Aurinia Pharmaceuticals follows in the paragraphs below.
Read the full article on Seeking Alpha
For further details see:
Aurinia Pharmaceuticals Appears Undervalued